Inclusion Criteria:
• Participant has a documented diagnosis of MDS according to WHO 2016 classification that
meets International Prognostic Scoring System Revised (IPSS-R) classification of low- or
intermediate-risk disease (IPSS-R score between 1.5 and 4.5).
MDS diagnosis, WHO classification, and IPSS-R risk classification will be prospectively
determined by independent central pathology and cytogenetics review, and applicable central
laboratory results.
• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0, 1, or 2.
Exclusion Criteria:
- Participants with prior malignancies must have an expected median life expectancy of
at least 12 months at the time of inclusion and no active treatment of any sort for at
least 24 weeks prior to randomization (including but not limited to immunotherapy or
targeted therapy)
- Hypoplastic Myelodysplastic Syndrome (MDS) with a marrow cellularity of ≤ 10%
- Participants diagnosed with MDS with excess blasts-2 (MDS-EB2)
- Prior treatment with azacitidine (any formulation), decitabine, or other
hypomethylating agent
Other protocol-defined inclusion/exclusion criteria apply
Recruiting
